At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
"Quick-starting" of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition: A Single-blind, Randomized Controlled, Non-inferiority Trial
In Brief
A clinical study evaluating Estetrol 15 mg/Drospirenone 3 mg (24/4) and Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7) for Ultrasound Finding: Ovulation Inhibition, Ovarian Activities and 2 related conditions. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The goal of this clinical trial is to learn if Estetrol/Drospirenone inhibit ovulation in quick-starting method. It will also learn about the safety of Estetrol/Drospirenone. The main questions it aims to answer are: 1. Does Estetrol/Drospirenone inhibit ovulation inferior to Ethinyl estradiol/Gestodene when starting on Day 7-9 of menstrual cycle? 2. What are the impacts of Estetrol/Drospirenone on ovarian activities when starting on Day 7-9 of menstrual cycle? 3. How does the cervical mucus change when starting Estetrol/Drospirenone on Day 7-9 of menstrual cycle? 4. What are the adverse effects when starting Estetrol/Drospirenone on Day 7-9 of menstrual cycle? Researchers will compare Estetrol/Drospirenone to Ethinyl estradiol/Gestodene to see if Estetrol/Drospirenone inhibit ovulation in quick-starting method.
Study Details
Timeline
Interventions
Completing a pack (28 pills) of Estetrol 15 mg/Drospirenone 3 mg (24/4), starting on day 7-9 of menstrual cycle
Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle